Every material Form 8-K Cocrystal Pharma, Inc. has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cocrystal Pharma announced on September 9, 2026 that the last subject has been dosed in its Phase 1b norovirus challenge study of CDI-988, an oral antiviral candidate. The company reported no serious adverse events to date and expects preliminary efficacy results in late 2026 or early 2027. The filing is a clinical development update and does not include financial results.
Last subject dosed in the Phase 1b challenge study (NCT07198139) evaluating CDI-988 as a preventive and treatment for norovirus
No serious adverse events reported to date
Preliminary efficacy results expected in late 2026 or early 2027
Primary endpoint is efficacy versus placebo in reducing the incidence of clinical symptoms; study conducted at Emory University School of Medicine
Cocrystal Pharma's Board of Directors appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately. The filing states there are no related party transactions or family relationships that require disclosure, and it does not describe her background or committee roles.
Board appointed Carol L. Brosgart as a director on August 12, 2026, effective immediately
Filing states no arrangements or understandings tied to her selection and no related party transactions requiring disclosure under Item 404(a)
Report signed by CFO James Martin on August 18, 2026
Cocrystal Pharma announced that Carol Brosgart, MD has joined its Board of Directors, effective August 12, 2026. The company said her antiviral drug development experience will support its CDI-988 norovirus program and broader antiviral pipeline.
Board appointment effective August 12, 2026; announced August 17, 2026
Dr. Brosgart spent more than a decade at Gilead Sciences, where she worked on Viread and Hepsera
Chairman Roger Kornberg said her insights will help advance CDI-988 for norovirus
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cocrystal Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →